DM1-SMe |
| Catalog No.GC18254 |
DM1-SMe es una forma no conjugada del maytansinoide en IMGN901. DM1-SMe es aproximadamente 3 a 10 veces mÁs potente que el fÁrmaco original Maytansine, con IC50 que van desde 0,003 a 0,01 nM para DM1-SMe en un panel de lÍneas de células tumorales humanas.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 138148-68-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
DM1-SMe is an analog of mertansine with a thiomethane cap attached to the sulfhydryl group. It has in vitro activity against the pediatric preclinical testing program (PPTP) panel of cancer cell lines with IC50 values of 0.002 to >3 nM.
References:
[1]. Wood, A.C., Maris, J.M., Gorlick, R., et al. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program Pediatr. Blood Cancer 60(11), 1860-1867 (2013).
Average Rating: 5 (Based on Reviews and 35 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *